Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

A technology for cardiovascular and cerebrovascular diseases and a composition is applied in the field of the combination of ginsenoside Rd and luteolin, which can solve the problems of large dosage and unsafe drug use.

Inactive Publication Date: 2012-01-11
GUIZHOU XINBANG PHARMACEUTICAL CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to combine two drugs with different action mechanisms, which can significantly reduce the infarct area of ​​the brain tissue, and significantly reduce the behavioral disorder caused by brain tissue necrosis. Since the drug interaction is a synergistic interaction, it is stronger than a single drug The additive effect of the entity; solve the problem of high and unsafe drug dosage; make the drug curative effect faster and stronger

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
  • Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
  • Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] The preparation of embodiment 1 injection

[0014] 1. Prescription:

[0015]

[0016] 2. Preparation:

[0017] Take ginsenoside-Rd, luteolin, sodium chloride, 1,2-propylene glycol; dissolve sodium chloride to 500ml of 20% propylene glycol aqueous solution, add ginsenoside-Rd and salvianolic acid B, and stir in a water bath at 60-70°C To complete dissolution, cool to room temperature, add the remaining amount of water for injection to 1000ml, mix and filter with a 0.22μm filter. The filtrate is filled in separate bottles, sealed, and sterilized to obtain the product.

Embodiment 2

[0018] The preparation of embodiment 2 dropping pills

[0019] 1. Prescription:

[0020]

[0021] 2. Preparation:

[0022] Take polyethylene glycol 6000, put it in a container, heat it to 70-80°C, wait until it is completely melted, and when the temperature drops to about 50°C, add ginsenoside Rd and luteolin to melt, and control the temperature at 40-50°C. Pour it into a dropping pill machine for dripping, drop it into simethicone oil, and make a dropping pill.

Embodiment 3

[0023] The preparation of embodiment 3 sublingual lozenge

[0024] 1. Prescription:

[0025]

[0026] 2. Take ginsenoside Rd, luteolin, hydroxypropylmethylcellulose (E-50), hydroxypropylmethylcellulose (E-4M), hydroxypropylcellulose, micronized silica gel, magnesium stearate Mix evenly with the method of increasing in equal amounts, and directly press into sublingual lozenges, that is to say.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and an application. The pharmaceutical composition takes ginsenoside Rd and luteolin as main components, is capable of obviously minimizing an infarction area of brain tissue and obviously mitigating the behavior obstacle due to necrotic brain tissue, and achieves the purpose of treating insufficiency of cerebral blood supply, cerebral thrombus, brain embolism, cerebrovascular spasm, brain dysfunction, Alzheimer disease, parkinsons syndrome, cerebral apoplexy, hypertension, hyperlipoidemia, arteriosclerosis, coronary heart disease, angina pectoris and miocardial infarction.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition for cardiovascular and cerebrovascular diseases. Specifically, the medicine involved is a combination of ginsenoside Rd and luteolin, which belongs to the technical field of medicines. Background technique: [0002] Cardiovascular and cerebrovascular diseases are characterized by high morbidity, disability, mortality and recurrence, and are one of the biggest killers threatening human health. According to epidemiological surveys, the incidence of cerebrovascular diseases worldwide is 1.4-200 / 100,000 population, and the average death rate is 100 / 100,000 population. With the aggravation of population aging, cerebrovascular disease, especially ischemic cerebrovascular disease has increasingly become one of the major diseases that threaten human health. It has brought a heavy burden and has attracted widespread attention from all countries in the world. The mortality rate of cerebrovascular disease i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/352A61P9/00A61P9/10A61P7/02A61P25/28A61P25/16A61P9/12A61P3/06
Inventor 张观福
Owner GUIZHOU XINBANG PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap